Literature DB >> 1706216

Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases.

D J Grignon1, J Y Ro, A G Ayala, D E Johnson, N G Ordóñez.   

Abstract

Adenocarcinomas account for approximately 2% of primary epithelial malignancies of the urinary bladder. The clinicopathologic features of 72 cases treated at one institution are reported; 22 cases were evaluated immunohistochemically. Twenty-four tumors were urachal and 48 nonurachal. The cases were analyzed according to their stage at presentation, histologic type, and mucin staining; they were tested immunohistochemically to determine their reaction to carcinoembryonic antigen, Leu-M1, prostate-specific antigen, and prostatic acid phosphatase. Tumor stage was a highly significant predictor of outcome (P = 0.001). Nonurachal tumors tended to have a worse outcome than urachal, but the difference was not statistically significant (P = 0.07). Histologic type was not a significant predictor of outcome (P = 0.10). For adenocarcinoma of the urinary bladder, stage was the most significant predictive factor; separating urachal from nonurachal tumors was important, but mucin histochemistry and immunohistochemistry did not help in this distinction. On occasion, a few tumors may react with some polyclonal antibodies to prostate-specific antigen; thus these results must be interpreted with caution. In these instances, the possibility of using highly sensitive and specific monoclonal antibodies such as the one employed in this study should be considered.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706216     DOI: 10.1002/1097-0142(19910415)67:8<2165::aid-cncr2820670827>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  50 in total

1.  Recurrent urachal adenocarcinoma.

Authors:  D Besarani; C A Purdie; N H Townell
Journal:  J Clin Pathol       Date:  2003-11       Impact factor: 3.411

2.  Urachal adenocarcinoma in situ with pseudomyxoma peritonei: a case report.

Authors:  G Stenhouse; D McRae; A M Pollock
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

3.  [Villous adenoma within an urachal diverticulum associated with long-term mucusuria].

Authors:  S Macher-Goeppinger; S Aulmann; A Haferkamp; M Hohenfellner; P Schirmacher; H Bläker
Journal:  Pathologe       Date:  2008-07       Impact factor: 1.011

4.  Signet Ring Cell Carcinoma of Urachal Origin Presenting as Irritative Lower Urinary Tract Symptoms and Pain Abdomen: A Rare Case Report.

Authors:  Amit Verma; Vinay Tomar
Journal:  J Clin Diagn Res       Date:  2016-07-01

5.  Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour.

Authors:  Neil Pugashetti; Stanley A Yap; Primo N Lara; Regina Gandour-Edwards; Marc A Dall'Era
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

Review 6.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

7.  [Urachal Cancer: an update of current molecular findings].

Authors:  H Reis; F Mairinger; S Ting; N Nagy; K E Witzke; M Kohl; B Sitek; C Niedworok; B Hadaschik; P Nyirády; T Szarvas
Journal:  Pathologe       Date:  2019-12       Impact factor: 1.011

Review 8.  Primary urachal malignancy: case report and literature review.

Authors:  D Hayes Ryan; P Paramanathan; N Russell; J Coulter
Journal:  Ir J Med Sci       Date:  2013-05-16       Impact factor: 1.568

9.  Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma.

Authors:  Geetha Vasudevan; Arijit Bishnu; Brij Mohan Kumar Singh; Deepak M Nayak; Pooja Jain
Journal:  J Clin Diagn Res       Date:  2017-03-01

10.  Penile metastasis from primay mucinous adenocarcinoma of bladder.

Authors:  Siddalingeshwar Neeli; Vikram Prabha; Sharan Alur; Prakash Malur
Journal:  Indian J Urol       Date:  2007-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.